BOYS MARK LAURENCE,DELISLE ROBERT KIRK,HICKEN ERIK JAMES,KENNEDY APRIL L.,MARESKA DAVID A.,MARMSATER FREDRIK P.,MUNSON MARK C.,NEWHOUSE BRAD,RAST BRYSON,RIZZI JAMES P.,RODRIGUEZ MARTHA E.,TOPALOV GEOR
申请号：
NZ61323511
公开号：
NZ613235A
申请日:
2011.12.13
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
The disclosure relates to a substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compound of formula (I) and pharmaceutically acceptable salts thereof in which the variables R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of type III receptor tyrosine kinases cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
